Market Analysis and Insights: Global Non-oncology Biopharmaceuticals Market
The research report studies the Non-oncology Biopharmaceuticals market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Non-oncology Biopharmaceuticals market size is projected to reach US$ 531430 million by 2027, from US$ 295620 million in 2020, at a CAGR of 8.3% during 2021-2027.
Global Non-oncology Biopharmaceuticals Scope and Segment
The global Non-oncology Biopharmaceuticals market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-oncology Biopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Biologics
Biosimilars
by Application, this report covers the following segments
Immunology
Endocrinology
Others
Global Non-oncology Biopharmaceuticals market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Non-oncology Biopharmaceuticals key players in this market include:
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen
The research report studies the Non-oncology Biopharmaceuticals market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Non-oncology Biopharmaceuticals market size is projected to reach US$ 531430 million by 2027, from US$ 295620 million in 2020, at a CAGR of 8.3% during 2021-2027.
Global Non-oncology Biopharmaceuticals Scope and Segment
The global Non-oncology Biopharmaceuticals market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-oncology Biopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Biologics
Biosimilars
by Application, this report covers the following segments
Immunology
Endocrinology
Others
Global Non-oncology Biopharmaceuticals market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Non-oncology Biopharmaceuticals key players in this market include:
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen
1 Market Overview of Non-oncology Biopharmaceuticals
1.1 Non-oncology Biopharmaceuticals Market Overview
1.1.1 Non-oncology Biopharmaceuticals Product Scope
1.1.2 Non-oncology Biopharmaceuticals Market Status and Outlook
1.2 Global Non-oncology Biopharmaceuticals Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Non-oncology Biopharmaceuticals Market Size by Region (2016-2027)
1.4 Global Non-oncology Biopharmaceuticals Historic Market Size by Region (2016-2021)
1.5 Global Non-oncology Biopharmaceuticals Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.1 North America Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.2 Europe Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.4 Latin America Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.5 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2016-2027)
2 Non-oncology Biopharmaceuticals Market Overview by Type
2.1 Global Non-oncology Biopharmaceuticals Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2016-2021)
2.3 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027)
2.4 Biologics
2.5 Biosimilars
3 Non-oncology Biopharmaceuticals Market Overview by Application
3.1 Global Non-oncology Biopharmaceuticals Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2016-2021)
3.3 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027)
3.4 Immunology
3.5 Endocrinology
3.6 Others
4 Non-oncology Biopharmaceuticals Competition Analysis by Players
4.1 Global Non-oncology Biopharmaceuticals Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020)
4.3 Date of Key Players Enter into Non-oncology Biopharmaceuticals Market
4.4 Global Top Players Non-oncology Biopharmaceuticals Headquarters and Area Served
4.5 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
4.6 Competitive Status
4.6.1 Non-oncology Biopharmaceuticals Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Non-oncology Biopharmaceuticals Products, Services and Solutions
5.1.4 Roche Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.1.5 Roche Recent Developments
5.2 Sanofi
5.2.1 Sanofi Profile
5.2.2 Sanofi Main Business
5.2.3 Sanofi Non-oncology Biopharmaceuticals Products, Services and Solutions
5.2.4 Sanofi Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.2.5 Sanofi Recent Developments
5.3 Johnson & Johnson
5.5.1 Johnson & Johnson Profile
5.3.2 Johnson & Johnson Main Business
5.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Products, Services and Solutions
5.3.4 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.3.5 Pfizer Recent Developments
5.4 Pfizer
5.4.1 Pfizer Profile
5.4.2 Pfizer Main Business
5.4.3 Pfizer Non-oncology Biopharmaceuticals Products, Services and Solutions
5.4.4 Pfizer Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.4.5 Pfizer Recent Developments
5.5 Novo Nordisk
5.5.1 Novo Nordisk Profile
5.5.2 Novo Nordisk Main Business
5.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Products, Services and Solutions
5.5.4 Novo Nordisk Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.5.5 Novo Nordisk Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Non-oncology Biopharmaceuticals Products, Services and Solutions
5.6.4 Novartis Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.6.5 Novartis Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Non-oncology Biopharmaceuticals Products, Services and Solutions
5.7.4 Merck Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.7.5 Merck Recent Developments
5.8 Teva
5.8.1 Teva Profile
5.8.2 Teva Main Business
5.8.3 Teva Non-oncology Biopharmaceuticals Products, Services and Solutions
5.8.4 Teva Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.8.5 Teva Recent Developments
5.9 Eli Lilly
5.9.1 Eli Lilly Profile
5.9.2 Eli Lilly Main Business
5.9.3 Eli Lilly Non-oncology Biopharmaceuticals Products, Services and Solutions
5.9.4 Eli Lilly Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.9.5 Eli Lilly Recent Developments
5.10 Bristol-Myers Squibb
5.10.1 Bristol-Myers Squibb Profile
5.10.2 Bristol-Myers Squibb Main Business
5.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Products, Services and Solutions
5.10.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.10.5 Bristol-Myers Squibb Recent Developments
5.11 GlaxoSmithKline
5.11.1 GlaxoSmithKline Profile
5.11.2 GlaxoSmithKline Main Business
5.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Products, Services and Solutions
5.11.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.11.5 GlaxoSmithKline Recent Developments
5.12 UCB Pharma
5.12.1 UCB Pharma Profile
5.12.2 UCB Pharma Main Business
5.12.3 UCB Pharma Non-oncology Biopharmaceuticals Products, Services and Solutions
5.12.4 UCB Pharma Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.12.5 UCB Pharma Recent Developments
5.13 Amgen
5.13.1 Amgen Profile
5.13.2 Amgen Main Business
5.13.3 Amgen Non-oncology Biopharmaceuticals Products, Services and Solutions
5.13.4 Amgen Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.13.5 Amgen Recent Developments
5.14 AbbVie
5.14.1 AbbVie Profile
5.14.2 AbbVie Main Business
5.14.3 AbbVie Non-oncology Biopharmaceuticals Products, Services and Solutions
5.14.4 AbbVie Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.14.5 AbbVie Recent Developments
5.15 Takeda
5.15.1 Takeda Profile
5.15.2 Takeda Main Business
5.15.3 Takeda Non-oncology Biopharmaceuticals Products, Services and Solutions
5.15.4 Takeda Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.15.5 Takeda Recent Developments
5.16 AstraZeneca
5.16.1 AstraZeneca Profile
5.16.2 AstraZeneca Main Business
5.16.3 AstraZeneca Non-oncology Biopharmaceuticals Products, Services and Solutions
5.16.4 AstraZeneca Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.16.5 AstraZeneca Recent Developments
5.17 Mylan
5.17.1 Mylan Profile
5.17.2 Mylan Main Business
5.17.3 Mylan Non-oncology Biopharmaceuticals Products, Services and Solutions
5.17.4 Mylan Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.17.5 Mylan Recent Developments
5.18 LEO Pharma
5.18.1 LEO Pharma Profile
5.18.2 LEO Pharma Main Business
5.18.3 LEO Pharma Non-oncology Biopharmaceuticals Products, Services and Solutions
5.18.4 LEO Pharma Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.18.5 LEO Pharma Recent Developments
5.19 Boehringer Ingelheim
5.19.1 Boehringer Ingelheim Profile
5.19.2 Boehringer Ingelheim Main Business
5.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Products, Services and Solutions
5.19.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.19.5 Boehringer Ingelheim Recent Developments
5.20 Alexion Pharmaceuticals
5.20.1 Alexion Pharmaceuticals Profile
5.20.2 Alexion Pharmaceuticals Main Business
5.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Products, Services and Solutions
5.20.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.20.5 Alexion Pharmaceuticals Recent Developments
5.21 Elusys Therapeutics
5.21.1 Elusys Therapeutics Profile
5.21.2 Elusys Therapeutics Main Business
5.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Products, Services and Solutions
5.21.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.21.5 Elusys Therapeutics Recent Developments
5.22 Swedish Orphan Biovitrum
5.22.1 Swedish Orphan Biovitrum Profile
5.22.2 Swedish Orphan Biovitrum Main Business
5.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Products, Services and Solutions
5.22.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.22.5 Swedish Orphan Biovitrum Recent Developments
5.23 Biogen
5.23.1 Biogen Profile
5.23.2 Biogen Main Business
5.23.3 Biogen Non-oncology Biopharmaceuticals Products, Services and Solutions
5.23.4 Biogen Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.23.5 Biogen Recent Developments
6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Non-oncology Biopharmaceuticals Market Dynamics
11.1 Non-oncology Biopharmaceuticals Industry Trends
11.2 Non-oncology Biopharmaceuticals Market Drivers
11.3 Non-oncology Biopharmaceuticals Market Challenges
11.4 Non-oncology Biopharmaceuticals Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Non-oncology Biopharmaceuticals Market Overview
1.1.1 Non-oncology Biopharmaceuticals Product Scope
1.1.2 Non-oncology Biopharmaceuticals Market Status and Outlook
1.2 Global Non-oncology Biopharmaceuticals Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Non-oncology Biopharmaceuticals Market Size by Region (2016-2027)
1.4 Global Non-oncology Biopharmaceuticals Historic Market Size by Region (2016-2021)
1.5 Global Non-oncology Biopharmaceuticals Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.1 North America Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.2 Europe Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.4 Latin America Non-oncology Biopharmaceuticals Market Size (2016-2027)
1.6.5 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2016-2027)
2 Non-oncology Biopharmaceuticals Market Overview by Type
2.1 Global Non-oncology Biopharmaceuticals Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2016-2021)
2.3 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027)
2.4 Biologics
2.5 Biosimilars
3 Non-oncology Biopharmaceuticals Market Overview by Application
3.1 Global Non-oncology Biopharmaceuticals Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2016-2021)
3.3 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027)
3.4 Immunology
3.5 Endocrinology
3.6 Others
4 Non-oncology Biopharmaceuticals Competition Analysis by Players
4.1 Global Non-oncology Biopharmaceuticals Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020)
4.3 Date of Key Players Enter into Non-oncology Biopharmaceuticals Market
4.4 Global Top Players Non-oncology Biopharmaceuticals Headquarters and Area Served
4.5 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
4.6 Competitive Status
4.6.1 Non-oncology Biopharmaceuticals Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Non-oncology Biopharmaceuticals Products, Services and Solutions
5.1.4 Roche Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.1.5 Roche Recent Developments
5.2 Sanofi
5.2.1 Sanofi Profile
5.2.2 Sanofi Main Business
5.2.3 Sanofi Non-oncology Biopharmaceuticals Products, Services and Solutions
5.2.4 Sanofi Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.2.5 Sanofi Recent Developments
5.3 Johnson & Johnson
5.5.1 Johnson & Johnson Profile
5.3.2 Johnson & Johnson Main Business
5.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Products, Services and Solutions
5.3.4 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.3.5 Pfizer Recent Developments
5.4 Pfizer
5.4.1 Pfizer Profile
5.4.2 Pfizer Main Business
5.4.3 Pfizer Non-oncology Biopharmaceuticals Products, Services and Solutions
5.4.4 Pfizer Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.4.5 Pfizer Recent Developments
5.5 Novo Nordisk
5.5.1 Novo Nordisk Profile
5.5.2 Novo Nordisk Main Business
5.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Products, Services and Solutions
5.5.4 Novo Nordisk Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.5.5 Novo Nordisk Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Non-oncology Biopharmaceuticals Products, Services and Solutions
5.6.4 Novartis Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.6.5 Novartis Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Non-oncology Biopharmaceuticals Products, Services and Solutions
5.7.4 Merck Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.7.5 Merck Recent Developments
5.8 Teva
5.8.1 Teva Profile
5.8.2 Teva Main Business
5.8.3 Teva Non-oncology Biopharmaceuticals Products, Services and Solutions
5.8.4 Teva Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.8.5 Teva Recent Developments
5.9 Eli Lilly
5.9.1 Eli Lilly Profile
5.9.2 Eli Lilly Main Business
5.9.3 Eli Lilly Non-oncology Biopharmaceuticals Products, Services and Solutions
5.9.4 Eli Lilly Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.9.5 Eli Lilly Recent Developments
5.10 Bristol-Myers Squibb
5.10.1 Bristol-Myers Squibb Profile
5.10.2 Bristol-Myers Squibb Main Business
5.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Products, Services and Solutions
5.10.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.10.5 Bristol-Myers Squibb Recent Developments
5.11 GlaxoSmithKline
5.11.1 GlaxoSmithKline Profile
5.11.2 GlaxoSmithKline Main Business
5.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Products, Services and Solutions
5.11.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.11.5 GlaxoSmithKline Recent Developments
5.12 UCB Pharma
5.12.1 UCB Pharma Profile
5.12.2 UCB Pharma Main Business
5.12.3 UCB Pharma Non-oncology Biopharmaceuticals Products, Services and Solutions
5.12.4 UCB Pharma Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.12.5 UCB Pharma Recent Developments
5.13 Amgen
5.13.1 Amgen Profile
5.13.2 Amgen Main Business
5.13.3 Amgen Non-oncology Biopharmaceuticals Products, Services and Solutions
5.13.4 Amgen Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.13.5 Amgen Recent Developments
5.14 AbbVie
5.14.1 AbbVie Profile
5.14.2 AbbVie Main Business
5.14.3 AbbVie Non-oncology Biopharmaceuticals Products, Services and Solutions
5.14.4 AbbVie Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.14.5 AbbVie Recent Developments
5.15 Takeda
5.15.1 Takeda Profile
5.15.2 Takeda Main Business
5.15.3 Takeda Non-oncology Biopharmaceuticals Products, Services and Solutions
5.15.4 Takeda Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.15.5 Takeda Recent Developments
5.16 AstraZeneca
5.16.1 AstraZeneca Profile
5.16.2 AstraZeneca Main Business
5.16.3 AstraZeneca Non-oncology Biopharmaceuticals Products, Services and Solutions
5.16.4 AstraZeneca Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.16.5 AstraZeneca Recent Developments
5.17 Mylan
5.17.1 Mylan Profile
5.17.2 Mylan Main Business
5.17.3 Mylan Non-oncology Biopharmaceuticals Products, Services and Solutions
5.17.4 Mylan Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.17.5 Mylan Recent Developments
5.18 LEO Pharma
5.18.1 LEO Pharma Profile
5.18.2 LEO Pharma Main Business
5.18.3 LEO Pharma Non-oncology Biopharmaceuticals Products, Services and Solutions
5.18.4 LEO Pharma Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.18.5 LEO Pharma Recent Developments
5.19 Boehringer Ingelheim
5.19.1 Boehringer Ingelheim Profile
5.19.2 Boehringer Ingelheim Main Business
5.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Products, Services and Solutions
5.19.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.19.5 Boehringer Ingelheim Recent Developments
5.20 Alexion Pharmaceuticals
5.20.1 Alexion Pharmaceuticals Profile
5.20.2 Alexion Pharmaceuticals Main Business
5.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Products, Services and Solutions
5.20.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.20.5 Alexion Pharmaceuticals Recent Developments
5.21 Elusys Therapeutics
5.21.1 Elusys Therapeutics Profile
5.21.2 Elusys Therapeutics Main Business
5.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Products, Services and Solutions
5.21.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.21.5 Elusys Therapeutics Recent Developments
5.22 Swedish Orphan Biovitrum
5.22.1 Swedish Orphan Biovitrum Profile
5.22.2 Swedish Orphan Biovitrum Main Business
5.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Products, Services and Solutions
5.22.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.22.5 Swedish Orphan Biovitrum Recent Developments
5.23 Biogen
5.23.1 Biogen Profile
5.23.2 Biogen Main Business
5.23.3 Biogen Non-oncology Biopharmaceuticals Products, Services and Solutions
5.23.4 Biogen Non-oncology Biopharmaceuticals Revenue (US$ Million) & (2016-2021)
5.23.5 Biogen Recent Developments
6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Non-oncology Biopharmaceuticals Market Dynamics
11.1 Non-oncology Biopharmaceuticals Industry Trends
11.2 Non-oncology Biopharmaceuticals Market Drivers
11.3 Non-oncology Biopharmaceuticals Market Challenges
11.4 Non-oncology Biopharmaceuticals Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
